August 30, 2025 a 07:43 am

DXCM: Fundamental Ratio Analysis - DexCom, Inc.

DexCom, Inc. stock analysis

DexCom, Inc. is a leading player in the healthcare sector, specializing in continuous glucose monitoring systems. With a consistent focus on innovation, DexCom provides advanced solutions for diabetes management, enhancing the quality of life for millions globally. The company's strategic collaborations and cutting-edge products suggest a promising future.

Fundamental Rating

The fundamental analysis of DexCom indicates strengths in several financial ratios, though some areas such as debt need improvement.

Category Score Visual
Overall Score 3
Discounted Cash Flow 3
Return on Equity 5
Return on Assets 5
Debt to Equity 1
Price to Earnings 1
Price to Book 1

Historical Rating

The historical data provides insight into DexCom's financial performance over time, showing consistency in certain metrics.

Date Overall DCF ROE ROA Debt/Equity P/E P/B
2025-08-29 3 3 5 5 1 1 1
Previous 0 3 5 5 1 1 1

Analyst Targets

Analysts project a wide range for DexCom's stock price, indicating strong potential upside with some risks involved.

High Low Median Consensus
146 28.125 95 81.36
DexCom stock chart and targets

Analyst Sentiments

Analysts are predominantly positive on DexCom, with a majority recommending "Buy", supported by strong growth prospects.

Recommendation Count Visual
Strong Buy 1
Buy 36
Hold 11
Sell 1
Strong Sell 0

Conclusion

DexCom, Inc. showcases a robust business model with innovative products in the healthcare sector. While the debt levels warrant attention, the company's strong performance in other financial metrics reflects its potential for growth. Analyst targets demonstrate a general optimism, although the range of predictions indicates some volatility. Overall, DexCom remains an attractive investment prospect for those interested in the medical device field. Investors should consider the dynamic nature of the healthcare industry and market variations before investing.